Bioneer

Bioneer Corporation, established in 1992, is a South Korean entity specializing in advanced biotechnology research products, molecular diagnostics, pharmaceuticals, and probiotics. The company operates within the Business Services sector, offering a comprehensive suite of solutions for scientific research and healthcare. Its product portfolio includes reagents and consumables such as PCR and RT-PCR kits, real-time PCR systems, RNA interference technologies, chemicals, plastic consumables, and buffer solutions. Bioneer also provides critical services in sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher development, electrophoresis, genome-wide functional analysis, and magnetic separation. These services are supported by a range of instruments designed for conventional and real-time PCR, sample preparation, protein synthesis, centrifugation, vortex mixing, electrophoresis, spectrophotometry, and microbial culturing.

With a workforce of 500 - 1,000 employees, Bioneer generates substantial revenue, reported at $177.5M. The company's operational scope extends to molecular diagnostics, encompassing MDx technologies, human diagnostic kits, MDx extraction kits, and associated instruments, alongside products for animal diseases and nano-bio applications. Bioneer is committed to innovation and scientific advancement, evidenced by its extensive research and development capabilities. For insights into the people driving these innovations, you can Meet Bioneer's team. The company's single primary location is in Daejeon, South Korea.

Bioneer serves both business-to-business (B2B) and business-to-consumer (B2C) markets, indicating a broad market reach. Its ticker symbol is KRX: 064550. The company's strategic focus on biotechnology and diagnostics positions it as a key player in the life sciences industry, contributing to advancements in research, healthcare, and therapeutic development. Its diverse offerings caterView more...